Neoadjuvant therapy for breast cancer: updates and proceedings from the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer

A. Arnaout, J. Lee, K. Gelmon, B. Poirier, F. I. Lu, M. Akra, J. F. Boileau, K. Tonkin, H. Li, C. Illman, C. Simmons, D. Grenier

Abstract


Therapy for breast cancer involves a complex interplay of three main treatment modalities: surgery, systemic therapy, and radiation therapy. The Canadian Consortium for Locally Advanced Breast Cancer (LABC) was established with the goal to convene a strong multidisciplinary team of breast oncology clinicians and scientists who are dedicated to the advancement of labc research and treatment, with a vision to drive progress through increased collaboration across disciplines and throughout Canada. The most recent meeting in May 2017 highlighted the latest evidence and literature about the optimal use of neoadjuvant systemic therapy in breast cancer. There is a need for increased clinical and scientific collaboration and the development of guidelines for the use of emerging treatment strategies. The interactive meeting sessions fostered unique opportunities for academic debate and nurtured collaboration between the attendees.

 


Keywords


Breast cancer; diagnosis; treatment; neoadjuvant therapy; locally advanced disease; surgery; radiation

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.25.4153






Copyright © 2018 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)